What mattersShow
- Kenneth To and his team at ViewsML are tackling one of the persistent
- Primary sector: AI Infrastructure
- Open the company page to keep the follow-up signal in view.
Kenneth To and his team at ViewsML are tackling one of the persistent, high-friction bottlenecks in modern precision medicine: the sheer labor and cost associated with traditional tissue analysis. Their ambition is to transform the analysis of human tissue samples—the bedrock of diagnostic pathology—from a specialized, physical lab process into scalable, software-driven computation. This is not simply digitizing an existing workflow; it's building what they term 'the computational layer for next-generation diagnostics.'
At its core, ViewsML has engineered a platform capable of virtual immunohistochemistry (vIHC). Historically, identifying a biomarker—a specific molecular marker linked to a disease state—requires laborious chemical staining (like IHC) applied to a physical tissue slide. This process is slow, expensive, and can often destroy the very sample needed for follow-up testing. ViewsML’s solution uses advanced AI models to extract detailed, per-cell biomarker spatial and quantitative insights directly from a routine, standard Hematoxylin and Eosin (H&E) slide. This capability allows researchers to 'see' biomarker staining virtually, bypassing the traditional need for time-consuming chemical stain batches and significantly accelerating the time-to-insight from weeks to minutes.
By virtualizing immunohistochemistry, ViewsML shifts biomarker analysis from a resource-constrained physical lab procedure into a scalable, computational software utility, drastically improving speed and accessibility for precision medicine research.
The technical ingenuity lies in translating complex, molecular staining patterns into high-resolution digital data points using deep learning models trained on pathology images. By creating what they call the 'world’s first virtual biomarker library,' ViewsML is developing a reference database of these virtual profiles. This library acts as a standardizing resource, allowing clinicians and drug developers to compare biomarker expression patterns across vast datasets without the logistical constraints of wet lab processing. The backing from institutions like Mayo Clinic and capital from Wittington Ventures underscores the clinical significance of this move, demonstrating confidence in its ability to provide deeper, more reliable data from a single, precious sample.
Get the week’s essential Canadian tech.
Five minutes. One useful email. No noise.
Sources & technical notesShowHide
Where this story is grounded
Use the public signals, research inputs, and editorial framing here to understand how the story was built.
What to evaluate next
This box highlights the systems, workflows, and decisions the article helps you assess.
Stay in the signal after this story.
Follow the company page, then jump into the broader sector hub before you leave the story.
Keep the company context attached as you read the rest of the coverage.
Weekly Canadian tech signals, distilled for operators.
Subscribe to the signalFree weekly briefing • Unsubscribe anytime
A practical checklist for Canadian policy, privacy, procurement, and governance teams who need a quick way to sanity-check AI deployments before they scale.
Open resource